Epsilon-aminocaproic acid inhibits the activity of factor VIII inhibitors in patients with severe haemophilia A in vivo and in vitro

Kanjaksha Ghosh, Shrimati Shetty, Anil Pathare, Dipika Mohanty

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Haemophilia patients with inhibitors pose a formidable challenge for patient management. This is particularly problematic in developing countries, where porcine factor VIII, FEIBA, factor VIIa or immunoadsorption column are generally unavailable or unaffordable. Under these circumstances, any effective modality of affordable treatment is welcome. We investigated, both in vivo and in vitro, the effect of ε-aminocaproic acid (EACA) on the inhibitory activity of factor VIII inhibitor. It was found that in vitro EACA (final concentration 1.25-5 mg/ml) substantially inhibited the activity of the inhibitors, while the same concentration of EACA had no effect on other immunological reactions like red cell agglutination and immunofluorescence. The inhibitory action of EACA on factor VIII inhibitor was also confirmed in an improvised antigen-binding ELISA system. Further, the inhibitory activity of EACA was confirmed in 2 patients, in whom the inhibitory activity persisted for 15 min following infusion of EACA (100 mg/kg over 10 min). EACA was found to be even more effective in local wound application in patients of haemophilia A with inhibitors. EACA at the concentration cited did not act as an inhibitor of factor VIII inhibitor through occupancy of lysine binding sites. The inhibitory activity of EACA on factor VIII inhibitor was equally seen with recombinant factor VIII also; hence this action cannot be explained by its antifibrinolytic activity. Copyright (C) 2000 S. Karger AG, Basel.

Original languageEnglish
Pages (from-to)67-72
Number of pages6
JournalActa Haematologica
Volume103
Issue number2
Publication statusPublished - 2000

Fingerprint

Aminocaproic Acid
Factor VIII
Hemophilia A
In Vitro Techniques
Factor VIIa
Antifibrinolytic Agents
Agglutination
Developing Countries
Lysine
Fluorescent Antibody Technique
Swine
Enzyme-Linked Immunosorbent Assay
Binding Sites
Antigens

Keywords

  • Epsilon aminocaproic acid
  • Factor VIII
  • Haemophilia A
  • In vitro effect
  • In vivo effect
  • Inhibitors

ASJC Scopus subject areas

  • Hematology

Cite this

Epsilon-aminocaproic acid inhibits the activity of factor VIII inhibitors in patients with severe haemophilia A in vivo and in vitro. / Ghosh, Kanjaksha; Shetty, Shrimati; Pathare, Anil; Mohanty, Dipika.

In: Acta Haematologica, Vol. 103, No. 2, 2000, p. 67-72.

Research output: Contribution to journalArticle

@article{60a475b366334821bc704c2d47d0be92,
title = "Epsilon-aminocaproic acid inhibits the activity of factor VIII inhibitors in patients with severe haemophilia A in vivo and in vitro",
abstract = "Haemophilia patients with inhibitors pose a formidable challenge for patient management. This is particularly problematic in developing countries, where porcine factor VIII, FEIBA, factor VIIa or immunoadsorption column are generally unavailable or unaffordable. Under these circumstances, any effective modality of affordable treatment is welcome. We investigated, both in vivo and in vitro, the effect of ε-aminocaproic acid (EACA) on the inhibitory activity of factor VIII inhibitor. It was found that in vitro EACA (final concentration 1.25-5 mg/ml) substantially inhibited the activity of the inhibitors, while the same concentration of EACA had no effect on other immunological reactions like red cell agglutination and immunofluorescence. The inhibitory action of EACA on factor VIII inhibitor was also confirmed in an improvised antigen-binding ELISA system. Further, the inhibitory activity of EACA was confirmed in 2 patients, in whom the inhibitory activity persisted for 15 min following infusion of EACA (100 mg/kg over 10 min). EACA was found to be even more effective in local wound application in patients of haemophilia A with inhibitors. EACA at the concentration cited did not act as an inhibitor of factor VIII inhibitor through occupancy of lysine binding sites. The inhibitory activity of EACA on factor VIII inhibitor was equally seen with recombinant factor VIII also; hence this action cannot be explained by its antifibrinolytic activity. Copyright (C) 2000 S. Karger AG, Basel.",
keywords = "Epsilon aminocaproic acid, Factor VIII, Haemophilia A, In vitro effect, In vivo effect, Inhibitors",
author = "Kanjaksha Ghosh and Shrimati Shetty and Anil Pathare and Dipika Mohanty",
year = "2000",
language = "English",
volume = "103",
pages = "67--72",
journal = "Acta Haematologica",
issn = "0001-5792",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Epsilon-aminocaproic acid inhibits the activity of factor VIII inhibitors in patients with severe haemophilia A in vivo and in vitro

AU - Ghosh, Kanjaksha

AU - Shetty, Shrimati

AU - Pathare, Anil

AU - Mohanty, Dipika

PY - 2000

Y1 - 2000

N2 - Haemophilia patients with inhibitors pose a formidable challenge for patient management. This is particularly problematic in developing countries, where porcine factor VIII, FEIBA, factor VIIa or immunoadsorption column are generally unavailable or unaffordable. Under these circumstances, any effective modality of affordable treatment is welcome. We investigated, both in vivo and in vitro, the effect of ε-aminocaproic acid (EACA) on the inhibitory activity of factor VIII inhibitor. It was found that in vitro EACA (final concentration 1.25-5 mg/ml) substantially inhibited the activity of the inhibitors, while the same concentration of EACA had no effect on other immunological reactions like red cell agglutination and immunofluorescence. The inhibitory action of EACA on factor VIII inhibitor was also confirmed in an improvised antigen-binding ELISA system. Further, the inhibitory activity of EACA was confirmed in 2 patients, in whom the inhibitory activity persisted for 15 min following infusion of EACA (100 mg/kg over 10 min). EACA was found to be even more effective in local wound application in patients of haemophilia A with inhibitors. EACA at the concentration cited did not act as an inhibitor of factor VIII inhibitor through occupancy of lysine binding sites. The inhibitory activity of EACA on factor VIII inhibitor was equally seen with recombinant factor VIII also; hence this action cannot be explained by its antifibrinolytic activity. Copyright (C) 2000 S. Karger AG, Basel.

AB - Haemophilia patients with inhibitors pose a formidable challenge for patient management. This is particularly problematic in developing countries, where porcine factor VIII, FEIBA, factor VIIa or immunoadsorption column are generally unavailable or unaffordable. Under these circumstances, any effective modality of affordable treatment is welcome. We investigated, both in vivo and in vitro, the effect of ε-aminocaproic acid (EACA) on the inhibitory activity of factor VIII inhibitor. It was found that in vitro EACA (final concentration 1.25-5 mg/ml) substantially inhibited the activity of the inhibitors, while the same concentration of EACA had no effect on other immunological reactions like red cell agglutination and immunofluorescence. The inhibitory action of EACA on factor VIII inhibitor was also confirmed in an improvised antigen-binding ELISA system. Further, the inhibitory activity of EACA was confirmed in 2 patients, in whom the inhibitory activity persisted for 15 min following infusion of EACA (100 mg/kg over 10 min). EACA was found to be even more effective in local wound application in patients of haemophilia A with inhibitors. EACA at the concentration cited did not act as an inhibitor of factor VIII inhibitor through occupancy of lysine binding sites. The inhibitory activity of EACA on factor VIII inhibitor was equally seen with recombinant factor VIII also; hence this action cannot be explained by its antifibrinolytic activity. Copyright (C) 2000 S. Karger AG, Basel.

KW - Epsilon aminocaproic acid

KW - Factor VIII

KW - Haemophilia A

KW - In vitro effect

KW - In vivo effect

KW - Inhibitors

UR - http://www.scopus.com/inward/record.url?scp=0033846632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033846632&partnerID=8YFLogxK

M3 - Article

VL - 103

SP - 67

EP - 72

JO - Acta Haematologica

JF - Acta Haematologica

SN - 0001-5792

IS - 2

ER -